On Tuesday, March 5, 2024, the Medical Imaging Drugs Advisory Committee will discuss efficacy and safety data submitted by submitted by Lumicell in support of a new drug application (NDA) 214511 for pegulicianine for injection. The proposed indication for pegulicianine is for use in patients with breast cancer to assist in the detection of cancerous tissue within the lumpectomy cavity following removal of the primary specimen during lumpectomy surgery.